Boston type I keratoprosthesis. Review

Arquivos Brasileiros de Oftalmologia

Volumn 75, Issue 3, 2012, Pages 218-222

  Magalhães, Fernanda Pedreira ^a   de Sousa, Luciene Barbosa ^a   de Oliveira, Lauro Augusto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cornea; Corneal diseases surgery; Corneal transplantation; Prostheses and implants; Prosthesis design

Indexed keywords

CORNEA DISEASE; HUMAN; IMPLANTATION; METHODOLOGY; POSTOPERATIVE CARE; PROSTHESES AND ORTHOSES; PROSTHESIS; REVIEW; VISUAL ACUITY;

CORNEAL DISEASES; HUMANS; POSTOPERATIVE CARE; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; VISUAL ACUITY;

EID: 84867149359     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492012000300016     Document Type: Review

References (46)

1. Pellier de Quengsy G. Precis au cours d'operations sur la chirurgie des yeux. Paris: Didot; 1789.
2. Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston kerato-prosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007;47(2):61-71.
3. Gomaa A, Comyn O, Liu C. Keratoprosthesis in clinical practice - a review. Clin Experiment Ophthalmol. 2010;38(2):211-24.
4. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009;116(4):640-51.
5. Dohlman CH, Schneider HA, Doane MG. Prosthokeratoplasty. Am J Ophthalmol. 1974;77(5):694-700.
6. Ma JJ, Graney JM, Dohlman CH. Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure. Int Ophthalmol Clin. 2005;45(4):49-59.
7. Pujari S, Siddique SS, Dohlman CH, Chodosh J. The Boston keratoprosthesis type II: The Massachusetts Eye and Ear Infirmary experience. Cornea. 2011;30(12):1298-303.
8. Utine CA, Tzu J, Dunlap K, Akpek EK. Visual and clinical outcomes of explantation versus preservation of the intraocular lens during keratoprosthesis implantation. J Cataract Refract Surg. 2011;37(9):1615-22.
9. Harissi-Dagher M, Khan BF, Schaumberg DA, Dohlman CH. Importance of nutrition to corneal grafts when used as a carrier of the Boston Keratoprosthesis. Cornea. 2007;26(5):564-8.
10. Todani A, Ciolino JB, Ament JD, Colby KA, Pineda R, Belin MW, et al. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol. 2011;249(10):1515-8.
11. Zerbe BL, Belin MW, Ciolino JB. Results from the multicenter Boston Type 1 Kerato-prosthesis Study. Ophthalmology. 2006;113(10):1779-84.
12. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20(1):19-23.
13. Harissi-Dagher M, Dohlman CH. The Boston Keratoprosthesis in severe ocular trauma. Can J Ophthalmol. 2008;43(2):165-9.
14. Khan BF, Harissi-Dagher M, Pavan-Langston D, Aquavella JV, Dohlman CH. The Boston Keratoprosthesis in herpetic keratitis. Arch Ophthalmol. 2007;125(6):745-9.
15. Akpek EK, Harissi-Dagher M, Petrarca R, Butrus SI, Pineda R 2nd, Aquavella JV, et al. Outcomes of Boston Keratoprosthesis in aniridia: a retrospective multicenter study. Am J Ophthalmol. 2007;144(2):227-31.
16. Aquavella JV, Gearinger MD, Akpek EK, McCormick GJ. Pediatric keratoprosthesis. Ophthalmology. 2007;114(5):989-94.
17. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145(3):438-44.
18. Sejpal K, Yu F, Aldave AJ. The Boston keratoprosthesis in the management of corneallimbal stem cell deficiency. Cornea. 2011;30(11):1187-94.
19. Ciralsky J, Papaliodis GN, Foster CS, Dohlman CH, Chodosh J. Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm. 2010;18(4):275-80.
20. Colby KA, Koo EB. Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol. 2011;22(4):267-73.
21. Pineles SL, Ela-Dalman N, Rosenbaum AL, Aldave AJ, Velez FG. Binocular visual function in patients with Boston type I keratoprostheses. Cornea. 2010;29(12):1397-400.
22. Dohlman CH, Abad JC, Dudenhoefer EJ, Graney JM. Keratoprosthesis: beyond corneal Arq Bras Oftalmol. 2012;75(3):218-22 221
23. Khalifa YM, Moshirfar M. Improved centration of the type 1 Boston Keratoprosthesis in donor carrier tissue. Clin Ophthalmol. 2010;4:931-3.
24. Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28(8):896-901.
25. Barnes SD, Dohlamn CH, Durand ML. Fungal colonization and infection in Boston keratoprosthesis. Cornea. 2007;26(1):9-15.
26. Magalhães FP, Nascimento HM, Ecker DJ, Lowery K, Sampath R, Rosenblatt MI, et al. Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% povidone-iodine. Cornea. 2012 (Epub ahead of print).
27. Nouri M, Terada H, Alfonso EC, Foster CS, Durand ML, Dohlman CH. Endophthalmitis after keratoprosthesis. Incidence, bacterial causes, and risk factors. Arch Ophthalmol. 2001;119(4):484-9.
28. Fintelmann RE, Maguire JI, Ho AC, Chew HF Ayres BD. Characteristics of endoph thalmitis in patients with the Boston keratoprosthesis. Cornea. 2009;28(8):877-8. Comment in: Characteristics of endophalmitis with Boston keratoprosthesis. Cornea. 2012.
29. Stacy RC, Jakobiec FA, Michaud NA, Dohlman CH, Colby KA. Characterization of retrokeratoprosthetic membranes in the Boston type 1 keratoprosthesis. Arch Ophthalmol. 2011;129(3):310-6.
30. Hicks CR, Hamilton S. Retroprosthetic membranes in Alpha-Cor patients: risk factors and prevention. Cornea. 2005;24(6):692-8.
31. Rudnisky CJ, Belin MW, Todani A, Al-Arfaj K, Ament JD, Zerbe BJ, Ciolino JB; Boston Type 1 Keratoprosthesis Study Group. Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results. Ophthalmology. 2012;119(5):951-5.
32. Stacy RC, Jakobiec FA, Michaud NA, Dohlman CH, Colby KA. Characterization of retrokeratoprosthetic membranes in the Boston type 1 keratoprosthesis. Arch Ophthalmol. 2011;129(3):310-6.
33. Ray S, Khan BF, Dohlman CH, D'Amico DJ. Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol. 2002;120(5):559-66.
34. Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr Opin Ophthalmol. 2011;22(2):133-6.
35. Kamyar R, Weizer JS, de Paula FH, Stein JD, Moroi SE, John D, et al. Glaucoma associated with Boston type I keratoprosthesis. Cornea. 2012;31(2):134-9.
36. Li JY, Greiner MA, Brandt JD, Lim MC, Mannis MJ. Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis. Am J Ophthalmol. 2011;152(2):209-18.
37. Talajic JC, Agoumi Y, Gané S, Moussally K, Harissi-Dagher M. Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery. Am J Ophthalmol. 2012;153(2):267-74.
38. Dohlman CH, Grosskreutz CL, Chen TC, Pasquale LR, Rubin PA, Kim EC, et al. Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery. J Glaucoma. 2010;19(2):111-5.
39. Dunlap K, Chak G, Aquavella JV, Myrowitz E, Utine CA, Akpek E. Short-term visual outcomes of Boston type 1 keratoprosthesis implantation. Ophthalmology 2010;117(4):687-92.
40. Bradley JC, Hernandez EG, Schawb IR, Mannis MJ. Boston type I keratoprosthesis: the University of California Davis experience. Cornea. 2009;28(3):321-7.
41. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston Type 1 keratoprosthesis at the University of California, Davis experience. Ophthalmology. 2011;118(8):1543-50.
42. Todani A, Behlau I, Fava MA, Cade F, Cherfan DG, Zakka FR, et al. Intraocular pressure measurement by radio wave telemetry. Invest Ophthalmol Vis Sci. 2011;52(13):9573-80.
43. Ciolino JB, Dohlman CH, Kohane DS. Contact lenses for drug delivery. Semin Ophthalmol. 2009;24(3):156-60.
44. Ament JD, Spurr-Michaud SJ, Dohlman CH, Gipson IK. The Boston Keratoprosthesis: comparing corneal epithelial cell compatibility with titanium and PMMA. Cornea. 2009;28(7):808-11.
45. Behlau I, Mukherjee K, Todani A, Tisdale AS, Cade F, Wang L, et al. Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials. Biomaterials. 2011;32(34):8783-96.
46. Wang L, Jeong KJ, Chiang HH, Zurakowski D, Behlau I, Chodosh J, et al. Hydroxyapatite for keratoprosthesis biointegration. Invest Ophthalmol Vis Sci. 2011;52(10):7392-9.